Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Autor:
Junji Tsurutani, Iori Taki-Takemoto, Kaori Nakatani, Motoi Ohba, Tohru Ohmori, Toshimitsu Yamaoka, Ken-Ichi Fujita, Daisuke Kamei, Satoru Arata, Shinichi Iwai, Sojiro Kusumoto
Publikováno v:
Molecular Cancer Therapeutics. 18:112-126
The critical T790M mutation in EGFR, which mediates resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKI; gefitinib, erlotinib, and afatinib), has facilitated the development of third-generation mutation-selective EGFR TKIs
Publikováno v:
Cancer Research. 81:1431-1431
Osimeritinib (OR), a Tyrosine Kinase Inhibitor is a first-line therapy in EGFR-mutant NSCLC patients. Resistance to OR treatment may occur due to acquired C797S mutations, MET amplifications and ALK rearrangements and other mechanisms not clearly def
Autor:
Ryan J. Hartmaier, Martin Johnson, Helen Tomkinson, Ganesh Mugundu, James Dunyak, Aleksandra Markovets, Juliann Chmielecki, Karthick Vishwanathan, Carl Barrett, Philip Overend
Publikováno v:
Cancer Research. 80:CT024-CT024
Circulating tumor DNA is released into the bloodstream from tumors and can reflect both intra-tumor heterogeneity and clonal evolution.1 As ctDNA levels are thought to reflect tumor burden, a decrease in ctDNA while on therapy may suggest treatment e
Autor:
Soo-Hwan Lee, Seo-Yoon Jeong, Min Hee Hong, Seok-Young Kim, Hye Ryun Kim, Byoung Chul Cho, Jiyeon Yun, Chae Won Park
Publikováno v:
Cancer Research. 80:5198-5198
Background: 1st generation (erlotinib & gefitinib), 2nd generation (afatinib), and 3rd generation (osimertinib) EGFR TKIs have marked efficacy in patient with EGFR-mutant NSCLC. Unfortunately, patients who show T790M (-) mutation after treated with 1
Autor:
Pasi A. Jänne, Christine A. Lydon, Lynette M. Sholl, Mizuki Nishino, Emily Chambers, Natalie I. Vokes, Eliezer M. Van Allen, Tom C. Nguyen
Publikováno v:
Cancer Research. 80:5882-5882
Background: Oncogenic mutations in EGFR are powerful biomarkers of response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, there remains significant heterogeneity in duration of response to therapy and overa
Abstract 3999: Advanced lung adenocarcinoma cell bank (ALACB) : A comprehensive preclinical platform
Autor:
Hyeong-Seok Joo, Ji-Yeon Lee, Seok-Young Kim, Byoung Chul Cho, Dong Hwi Kim, Han-Na Kang, Mi-ran Yun, Hye Ryun Kim
Publikováno v:
Cancer Research. 79:3999-3999
Purpose: Patients with advanced lung adenocarcinoma often lack large clinical specimens required for molecular testing which limits next therapeutic options. Patient-derived cells (PDC) from malignant effusions can predict patient drug responses and
Publikováno v:
Cancer Research. 78:1522-1522
The recent FDA approvals of palbociclib, ribociclib, and abemaciclib in breast cancer validate cyclin-dependent kinases 4 and 6 (CDK4/6) as key therapeutic targets, and warrant investigations in other tumor types with frequently observed alterations
Autor:
Clive Morris, Solène Marteau, Camille Leonce, Lionel Falchero, Pierre Saintingy, Gilles Clapisson, Maurice Pérol, Virginie Avrillon, Pierre Fournel, Sandra Ortiz-Cuaran, Emma Green, Luc Odier, Aurélie Swalduz, Séverine Martinez
Publikováno v:
Cancer Research. 78:937-937
Background: In EGFR-mutant non-small cell lung cancer (NSCLC), progression disease (PD) under 1st-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) is driven by the EGFR T790M mutation in about 50% of cases. This mutation is targeted with osimer
Autor:
Luiz F. L. Reis, Manoel Cruz, Franciele Hinterholz Knebel, Joao Victor Machado Alessi, Anamaria A. Camargo, Andrea K. Shimada, Fabiana Bettoni, Marcelo V. Negrao, Artur Katz
Publikováno v:
Clinical Cancer Research. 24:B03-B03
Osimertinib is an EGFR-T790M-specific TKI, which has demonstrated impressive response rates in NSCLC, after failure to first-line anti-EGFR TKIs. However, acquired resistance to osimertinib is also observed and the molecular mechanisms of resistance
Autor:
Katsuhiko Naoki, Shigenari Nukaga, Toshiyuki Hirano, Tomoko Betsuyaku, Keita Masuzawa, Junko Hamamoto, Kenzo Soejima, Hiroyuki Yasuda, Hanako Hasegawa
Publikováno v:
Cancer Research. 77:2099-2099
Purpose: Multiple EGFR-TKIs are available and under development to treat patients with lung cancer harboring EGFR mutations. Nazartinib is one of the 3rd generation EGFR-TKIs targeting EGFR T790M as well as common mutations such as L858R and exon 19